LPCN
Lipocine Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.46
−0.05%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.47
From 52W high−87.04%
Volume42420.00
Market cap$12.03M
P/E (TTM)—
P/S (TTM)7.7x
Div yield—
Key dataNov 4, 2026
Open
$1.47
From 52W high
−87.04%
Volume
42420.00
Market cap
$12.03M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.0x
P/E (TTM)
—
RSI (14)
32.1
MomentumView details →
1D Return
−0.05%
YTD Return
−82.00%
SummaryUpdated Jun 1, 2026
Lipocine Inc. (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company founded and headquartered in Salt Lake City, Utah. The company went public in October 2013 and specializes in developing oral delivery solutions for pharmaceutical products that treat neuroendocrine and metabolic disorders. Lipocine's core focus is on creating oral formulations of drugs that traditionally have poor bioavailability when taken by mouth, particularly hormone-based therapies. The company's lead product, TLANDO, is an oral testosterone replacement therapy that has received FDA approval, representing a significant milestone in the company's development trajectory.
Similar companies
Latest newsMore news →
Health Canada approved Lipocine’s TLANDO testosterone undecanoate capsules for testosterone replacement therapy in adult males with male hypogonadism.28d agoLipocine Inc. announced the initiation of the BLOOM Phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression, with first participant dosing expected in early Q4 2026.51d ago